Intra-periaqueductal gray matter injections of midazolam fail to alter anxiety in plus-maze experienced mice

Brain Research

Volumn 1231, Issue , 2008, Pages 93-102

  dos Reis, Luciana Maria ^a   Canto de Souza, Azair ^a  

^a FEDERAL UNIVERSITY OF SÃO CARLOS   (Brazil)

Author keywords

Anxiety; EPM; Flumazenil; Midazolam; One trial tolerance; Periaqueductal gray

Indexed keywords

4 AMINOBUTYRIC ACID; BENZODIAZEPINE RECEPTOR; FLUMAZENIL; MIDAZOLAM;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; AVOIDANCE BEHAVIOR; CONTROLLED STUDY; DISEASE MODEL; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; ELEVATED PLUS MAZE TEST; ETHOLOGY; INTRAPERIAQUEDUCTAL GRAY MATTER DRUG ADMINISTRATION; LOCOMOTION; MALE; MAZE TEST; MESENCEPHALON; MOUSE; NONHUMAN; ONE TRIAL TOLERANCE; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; RISK ASSESSMENT; SCORING SYSTEM; SWISS WEBSTER MOUSE; VIDEORECORDER;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; ANXIETY DISORDERS; AVOIDANCE LEARNING; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEAR; FLUMAZENIL; GABA MODULATORS; GAMMA-AMINOBUTYRIC ACID; MALE; MAZE LEARNING; MICE; MIDAZOLAM; NEURAL INHIBITION; PERIAQUEDUCTAL GRAY; RECEPTORS, GABA-A; SYNAPTIC TRANSMISSION;

MUS; RODENTIA;

EID: 50949127095     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2008.06.042     Document Type: Article

References (76)

1. Agmo A., Galvan A., Heredia A., and Morales M. Naloxone blocks the antianxiety but not the effects of benzodiazepines and pentobarbital - experimental studies and literature. Psychopharmacology 120 2 (1995) 186-194
2. Albrechet-Souza L., Oliveira A.R., De-Luca M.C.Z., Tomazini F.M., Santos N.R., and Brandão M.L. A comparative study with two types of elevated plus-maze (transparent vs, opaque walls) on the anxiolytic effects of midazolam, one-trial tolerance and fear-induced analgesia. Prog. in Neuro-Psychopharmacol. Biol. Psychiatry 29 (2005) 571-579
3. Audi E.A., and Graeff F.G. Benzodiazepine receptors in the periaqueductal grey mediate anti-aversive drug action. Eur. J. Pharmacol. 103 (1984) 279-285
4. Babbini M., Gaiardi M., and Bartoletti M. Benzodiazepine effects upon Geller-Seifter conflict test in rats: analysis of individual variability. Pharmacol. Biochem. Behav. 17 1 (1982) 43-48
5. Becerra-Garcia A.M., Cardenas F.R., and Morato S. Effect of different illumination levels on rat behavior in the elevated plus-maze. Physiol. Behav. 85 (2005) 265-270
6. Bertoglio L.J., and Carobrez A.P. Previous maze experience required to increase open arms avoidance in rats submitted to the elevated plus-maze model of anxiety. Behav. Brain Res. 108 (2000) 197-203
7. Bertoglio L.J., and Carobrez A.P. Anxiolytic effects of ethanol and phenobarbital are abolished in test-experienced rats submitted to the elevated plus maze. Pharmacol., Biochem. Behav. 73 (2002) 963-969
8. Bertoglio L.J., and Carobrez A.P. Behavioral profile of rats submitted to session 1-session 2 in the elevated plus-maze during diurnal/nocturnal phases and under different illumination conditions. Behav. Brain Res. 132 (2002) 135-143
9. Bertoglio L.J., and Carobrez A.P. Prior maze experience required to alter midazolam effects in rats submitted to the elevated plus-maze. Pharmacol. Biochem. Behav. 72 (2002) 449-455
10. Bertoglio L.J., and Carobrez A.P. Anxiolytic-like effects of NMDA/glicine-B receptor ligands are abolished during the elevated plus-maze Trial 2 in rats. Psychopharmacology 170 (2003) 335-342
11. Bertoglio L.J., Anzini C., Lino-de-Oliveira C., and Carobrez A.P. Enhanced dorsolateral periaqueductal gray activity counteracts the anxiolytic response to midazolam on the elevated plus-maze Trial 2 in rats. Behav. Brain Res. 162 (2005) 99-107
12. Blanchard R.J., and Blanchard D.C. Attack and defense in rodents as ethoexperimental models for the study of emotion. Prog. in Neuro-psychopharmacol. Biol. Psychiatry 13 suppl. (1989) S3-S14
13. Brandão M.L., Aguiar J.C., and Graeff F.G. GABA mediation of antiaversive action of minor tranquilizers. Pharmacol., Biochem. Behav. 16 (1982) 397-402
14. Canto-de-Souza A., Nunes-de-Souza R.L., and Rodgers R.J. Anxiolytic-like effect of WAY-100635 microinfusions into the median (but not dorsal) raphe nucleus in mice exposed to the plus-maze: influence of prior test experience. Brain Res. 928 (2002) 50-59
15. Carobrez A.P., and Bertoglio L.J. Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20 years on. Neurosci. biobehav. rev. 29 (2005) 1193-1205
16. Cole J.C., and Rodgers R.J. An ethological analysis of the effects of chlordiazepoxide and bretazenil (Ro 16-6028) in the murine elevated plus maze. Behav. Pharmacol. 4 (1993) 573-580
17. Cruz A.P.M., Frei F., and Graeff F.G. Ethopharmacological analysis of rat behavior on the elevated plus-maze. Pharmacol. Biochem. Behav. 49 (1994) 171-176
18. Cruz-Morales S.E., Santos N.R., and Brandão M.L. One-trial tolerance to midazolam is due to enhancement of fear and reduction of anxiolytic-sensitive behaviors in the elevated plus-maze retest in the rat. Pharmacol. Biochem. Behav.r 72 (2002) 973-978
19. Dawson G.R., Crawford S.P., Stanhope K.J., Iversen S.D., and Tricklebank M.D. One-trial tolerance to the effects of chlordiazepoxide on the elevated plus-maze may be due to locomotor habituation, not repeated drug exposure. Psycopharmacology 113 (1994) 570-572
20. De Boer, S.F., Koolhaas, J.M., 2003. Defensive burying in rodents: ethology, neurobiology and psychopharmacology 463, 145-161.
21. Fernandes C., and File S.E. The influence of open arm ledges and maze experience in the elevated plus-maze. Pharmacol. Biochem. Behav. 54 (1996) 31-40
22. Ferris P., Seward E., and Dawson G.R. Interactions between LY354740, a group II metabotropic agonist and the GABA(A)-benzodiazepine receptor complex in the rat elevated plus-maze. J. Psychopharmacol. 15 (2001) 76-82
23. File S.E. One-trial tolerance to the anxiolytic effects of benzodiazepines in the plus-maze. Psychopharmacology 100 (1990) 281-282
24. File S.E. Behavioural detection of anxiolytic action. In: Elliott J.M., Heal D.J., and Marsden C.A. (Eds). Experimental Approaches to Anxiety and Depression (1992), J. Wiley, Chichester 25-44
25. File S.E. The interplay of learning and anxiety in the elevated plus-maze. Behav. Brain Res. 58 (1993) 199-202
26. File S.E., and Seth P. A review of 25 years of the interaction test. Eur. J. Pharmacol. 463 (2003) 35-53
27. File S.E., and Zangrossi H.J. One-trial tolerance to the anxiolytic actions of the benzodiazepines in the elevated plus-maze, or the development of a phobic state?. Psychopharmacology 110 (1993) 240-244
28. File S.E., Mabutt P.S., and Hitchott P.K. Characterization of phenomenon of "one-trial tolerance" to the anxiolytic effect of chlordiazepoxide in the elevated plus-maze. Psychopharmacology 102 (1990) 98-101
29. Franklin K.B., and Paxinos G. The Mouse Brain in Stereotaxic Coordinates. Ed. (1997), USA, Academic Press. Califórnia
30. Gonzalez L.E., and File S.E. A five-minute experience in the elevated plus-maze alters the state of the benzodiazepine receptor in the dorsal raphe nucleus. J. Neurosci. 17 (1997) 505-511
31. Graeff F.G. Neuroanatomy and neurotransmitter regulation of defensive behaviors and related emotions in mammals. Braz. J. Med. and Biol. Res. 27 4 (1994) 811-829
32. Graeff F.G., Brandão M.L., Audi E.A., and Schutz M.T.B. Modulation of the brain aversive system by GABAergic and serotonergic mechanisms. Behav. Brain Res. 21 (1986) 65-72
33. Graeff F.G., Silveira M.C.L., Nogueira R.L., Audi E.A., and Oliveira R.M.W. Role of the amygdala and periaqueductal gray in anxiety and panic. Behav. Brain Res. 58 1-2 (1993) 123-131
34. Green S., and Vale A. Role of amygdaloid nuclei in the anxiolytic effects of benzodiazepines in rats. Behav Pharmacol 3 (1992) 261-264
35. Griebel G., Sanger D.J., and Perrault G. The use of the rat plus-maze to discriminate non-selective and BZ-1 (w1) selective, benzodiazepine receptor ligands. Psychopharmacology 124 (1996) 245-254
36. Griebel G., Rodgers R.J., Perrault G., and Sanger D.J. Risk assessment behaviour: evaluation of utility in the study of 5-HT-related drugs in the elevated plus-maze. Pharmacol. Biochem. Behav. 57 (1997) 817-827
37. Handley S.L. Serotonin in animal models of anxiety: the importance of stimulus and response. In: Idzikowski C., and Cowen P.J. (Eds). Serotonin, Sleep and Mental Disorder (1991), Wrightson, London 89-115
38. Handley S.L., and Mithani S. Effects of alpha-adrenoceptor agonists and antagonists in a maze exploration model of "fear"-motivated behaviour. Naunyn-Schmiedeberg's Arch. Pharmacol. 327 (1984) 1-5
39. Hascoët M., Bourin M., and Dhonnchadha B.A.N. The mouse light-dark paradigm: a review. Prog. Neuro-Psychophamacol. Biol. Psychiatry 25 (2001) 141-166
40. Hogg S. A review of the validity and reliability of the elevated plus-maze as a model of anxiety. Pharmacol. Biochem. Behav. 54 (1996) 21-30
41. Holmes A., and Rodgers R.J. Responses of Swiss-Webster mice to repeated plus-maze experience: further evidence for qualitative shift in emotional state?. Pharmacol. Biochem. Behav. 60 (1998) 473-488
42. Holmes A., and Rodgers R.J. Influence of spatial and temporal manipulations on the anxiolytic efficacy of chlordiazepoxide in mice previously exposed to the elevated plus maze. Neurosci. Biobehav. Rev. 23 (1999) 971-980
43. Howard J.L., and Pollard G.T. Effects of buspirone in the Geller-Seifter conflict test with incremental shock. Drug Dev. Res. 19 1 (2004) 37-49
44. Hunkeler W., Mohler H., Pieri L., Polc P., Bonetti E.P., Cumin R., Schaffner R., and Haefely W. Selective antagonists of benzodiazepines. Nature 290 (1981) 514-516
45. Kennett G.A., Bailey F., Piper D.C., and Blackburn T.P. Effects of SB 2006464, a 5-HT2C 5-HT2B receptor antagonist, in 2 conflict models of anxiety. Psychopharmacology 118 2 (1995) 178-182
46. Kennett G.A., Trail B., and Bright F. Anxiolytic-like actions of BW 723C86 in the rat Vogel conflict test are 5-HT2B receptor mediated. Neuropharmacology 37 12 (1998) 1603-1610
47. Lee C., and Rodgers R.J. Effects of benzodiazepine receptor antagonist, flumazenil, on antinociceptive and behavioural responses to the elevated plus-maze in mice. Neuropharmacology 30 (1991) 1263-1267
48. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92 (1987) 180-185
49. Menard J., and Treit D. Effects of centrally administered anxiolytic compounds in animal models of anxiety. Neurosci. Biobehav. Rev. 23 (1999) 591-613
50. Mendes-Gomes J., and Nunes-de-Souza R.L. Concurrent nociceptive stimulation impairs the anxiolytic effect of midazolam injected into the periaqueductal gray in mice. Brain Res. 1047 (2005) 97-104
51. Milani H., and Graeff F.G. GABA-benzodiazepine modulation of aversion in the medial hypothalamus of the rat. Pharmacol. Biochem. and Behav. 28 (1987) 21-27
52. Millan M.J. The neurobiology and control of anxious states. Prog.Neurobiol. 70 2 (2003) 83-244
53. Motta V., and Brandão M.L. Aversive and antiaversive effects of morphine in the dorsal periaqueductal gray of rats submitted to the elevated plus-maze test. Pharmacol. Biochem. Behav. 44 (1993) 119-125
54. Nunes-de-Souza R.L., Canto-de-Souza A., Da-Costa M., Fornari R.V., Graeff F.G., and Pelá I.R. Anxiety-induced antinociception in mice: effects of systemic and intra-amygdala administration of 8-OH-DPAT and midazolam. Psychopharmacology 150 3 (2000) 300-310
55. Nunes-de-Souza R.L., Canto-de-Souza A., and Rodgers R.J. Effects of intra-hippocampal infusion of WAY-1000635 on plus-maze behavior in mice. Influence of site of injection and prior test experience. Brain Res. 927 (2002) 87-96
56. Pellow S., and File S.E. Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat. Pharmacol. Biochem. Behav. 24 (1986) 525-529
57. Pellow S., Chopin P., File S.E., and Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 14 (1985) 149-167
58. Pesold C., and Treit D. The septum and amygdala differentially mediate the anxiolytic effects of benzodiazepines. Brain Res. 638 (1994) 295-301
59. Pesold C., and Treit D. The central and basolateral amygdala differentially mediate the anxiolytic effects of benzodiazepines. Brain Res. 671 (1995) 213-221
60. Pesold C., and Treit D. The neuroanatomical specificity of the anxiolytic effects of intra-septal infusions of midazolam. Brain Res. 710 (1996) 161-168
61. Pietraszek M., Sukhanov I., Maciejak P., Szyndler J., Gravius A., Wislowska A., Plaznik A., Bespalov A., and Danysz W. Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats. Eur. J. Pharmacol. 514 (2005) 25-34
62. Prut L., and Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur. J. Pharmacol. 463 (2003) 3-33
63. Rodgers R.J., and Johnson N.J.T. Factor-analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol. Biochem. Behav. 2 (1995) 297-303
64. Rodgers R.J., and Shepherd J.K. Influence of prior maze experience on behavior and response to diazepam in the elevated plus-maze and light/dark tests of anxiety in mice. Psychopharmacology 113 (1993) 237-242
65. Rodgers R.J., Johnson N.J.T., Cole J.C., Dewar C.V., Kidd G.R., and Kimpson P.H. Plus-maze retest profile: importance of initial stages of trial 1 and response to post-trial cholinergic receptor blockade in mice. Pharmacol. Biochem. Behav. 54 (1996) 41-50
66. Rodgers R.J., Cutler M.G., and Jackson J.E. Behavioural effects in mice of subchronic chlordiazepoxide, maprotiline and fluvoxamine. II. The elevated plus-maze. Pharmacol. Biochem. Behav. 57 (1997) 127-136
67. Rosa V.P., Vandressen N., Calixto A.V., Kovaleski D.F., and Faria M.S. Temporal analysis of the rat's behavior in the plus-maze: effect of midazolam. Pharmacol. Biochem. Behav. 67 (2000) 177-182
68. Russo A.S., Guimarães F.S., De Aguiar J.C., and Graeff F.G. Role of benzodiazepine receptors located in the dorsal periaqueductal gray of rats in anxiety. Psychopharmacology 110 (1993) 198-2002
69. Savic M.M., Obradovic D.I., Ugresic N.D., Cook J.M., Yin W., and Bokonjic D.R. Bidirectional effects of benzodiazepine binding site ligands in the elevated plus-maze: differential antagonism by flumazenil and β-CCt. Pharmacol. Biochem. Behav. 79 (2004) 279-290
70. Shah A.A., and Treit D. Infusions of midazolam into the medial prefrontal cortex produce anxiolytic effects in the elevated plus-maze and shock-probe burying tests. Brain Res. 996 (2004) 31-40
71. Smith R.L., and Barret R.J. Tolerance to the anticonflict effects of diazepam: importance of methodological considerations. Pharmacol. Biochem. Behav. 58 1 (1997) 61-66
72. Stephens D.N., Meldrum B.S., Weidmann R., Schneider C., and Grutzner M. Does the excitatory amino acid receptor antagonist 2-APH exhibit anxiolytic activity?. Psychopharmacology 90 (1986) 166-169
73. Treit D. Anxiolytic effects of benzodiazepines and 5-HT1A agonists: a review. In: Rodgers R.J., and Cooper S.J. (Eds). 5-HT1A Agonists, 5-HT3 Agonists and Benzodiazepines: Their Comparative Behavioural Pharmacology (1991), J. Wiley, Chichester 107-131
74. Treit D., Menard J., and Royan C. Anxiogenic stimuli in the elevated plus-maze. Pharmacol. Biochem. Behav. 44 (1993) 463-469
75. Wada T., and Fukuda N. Effects of DN-2327, a new anxiolytic, diazepam and buspirone on exploratory activity of the rat in an elevated plus-maze. Psychopharmacology 104 (1991) 444-450
76. Zangrossi Jr. H., and Graeff F.G. Behavioural effects of intra-amygdala injections of GABA and 5-HT acting drugs in the elevated plus-maze. Braz. J. Med. Biol Res. 27 (1994) 2453-2456